stockrowBiorestorative Therapies, Inc.
BRTX Healthcare Biotechnology
Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024.
- Revenue
- −7.20%
- EPS
- +81.3%
- Free cash flow
- −35.3%
Quarter to March 2026, against a year earlier
Follow BRTX
Alert me
Biorestorative Therapies, Inc. (BRTX) EV/Sales
As of 6 November 2026, Biorestorative Therapies, Inc. (BRTX) trades at a EV/Sales of −5.8×. Over the past ten years it has ranged from −368× (January 2022) to 730× (October 2020); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 21.7× | 1,451.44% |
| FY2024 | 1.4× | — |
| FY2023 | −24.8× | — |
| FY2022 | −39.4× | — |
| FY2021 | −341× | — |
| FY2020 | 157× | 7,305.39% |
| FY2019 | 2.1× | (96.91%) |
| FY2018 | 68.5× | 354.00% |
| FY2017 | 15.1× | (66.21%) |
| FY2016 | 44.7× | 20,647.93% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 4.0× | (81.70%) |
| Dec 2025 | 21.7× | (6.72%) |
| Sep 2025 | 23.3× | 91.13% |
| Jun 2025 | 12.2× | (20.08%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. compare | −52.3× |
| BRTX Biorestorative Therapies, Inc. | −5.8× |
| APVO Aptevo Therapeutics Inc. compare | −0.4× |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| EDVA Splash Beverage Group, Inc. compare | 0.8× |
| HCWB HCW Biologics Inc. compare | 1.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)